SUMMIT European Cannabis Insights Summit 2026 — Exclusive industry intelligence Register Now
EVENT Cannabis Europa London 2026 — Europe's cannabis industry unites Get Tickets

Recent Searches

    Tilray’s Medical Cannabis Product Now Available And Reimbursed Under Ireland’s Medical Cannabis Access Program

    By

    PRESS RELEASE

    TILRAY Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, today announced that it has successfully relaunched its EU GMP-produced medical cannabis oral solution in Ireland under the country’s Medical Cannabis Access Program (MCAP). Tilray’s approved product has also recently received reimbursement approval, which gives patients cost reimbursement and ensures more eligible patients can access quality medical cannabis under Ireland’s MCAP.

    Denise Faltischek, Tilray Brands’ Chief Strategy Officer and Head of International Business, said, “We are extremely proud to relaunch in Ireland with an expanded footprint. The MCAP reimbursement approval is a tremendous step in providing patients with greater access to Tilray’s high-quality medical cannabis products that address their needs. We remain dedicated to do our part to increase access for patients in need around the world.”

    Patients in Ireland may now access Tilray’s full-spectrum medical cannabis oil solution through the MCAP. Tilray intends to supply Irish patients with its full suite of medical cannabis products when local regulations allow.

    Tilray Medical is a leading provider of EU-GMP certified medical cannabis products in 22 countries with a comprehensive portfolio of THC and CBD products. Each medical cannabis product that Tilray offers has been selected to ensure patients can receive both the highest product quality as well as consistency when it comes to supply of their medicinal cannabis products.

    About Tilray Medical 

    Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, and Symbios. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first EU-GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the biggest suppliers of medical cannabis brands to patients, physicians, hospitals, pharmacies, researchers, and governments, in 22 countries and across five continents.

    BusinessCann

    The Briefing / Newsletter

    Insights
    you don't want
    to miss.

    A comprehensive, thoughtfully curated overview of the stories defining today's cannabis sector — breaking news, investigative features, expert commentary, and context-rich analysis to help you navigate events with clarity and confidence.

    • Policy & regulation
    • Markets & deals
    • Clinical & science
    Subscribe free